Pieris Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Pieris Pharmaceuticals has been growing earnings at an average annual rate of 3.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 5.3% per year.
Belangrijke informatie
3.4%
Groei van de winst
14.4%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | -5.3% |
| Rendement op eigen vermogen | -127.3% |
| Nettomarge | -114.1% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%
Jul 11
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02Opbrengsten en kosten
Hoe Pieris Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 21 | -24 | 17 | 0 |
| 31 Mar 24 | 41 | -16 | 17 | 0 |
| 31 Dec 23 | 43 | -25 | 17 | 0 |
| 30 Sep 23 | 47 | -28 | 19 | 0 |
| 30 Jun 23 | 33 | -27 | 16 | 0 |
| 31 Mar 23 | 17 | -41 | 16 | 0 |
| 31 Dec 22 | 26 | -33 | 16 | 0 |
| 30 Sep 22 | 28 | -35 | 16 | 0 |
| 30 Jun 22 | 27 | -42 | 17 | 0 |
| 31 Mar 22 | 27 | -47 | 17 | 0 |
| 31 Dec 21 | 31 | -46 | 17 | 0 |
| 30 Sep 21 | 25 | -51 | 16 | 0 |
| 30 Jun 21 | 24 | -48 | 16 | 0 |
| 31 Mar 21 | 32 | -38 | 16 | 0 |
| 31 Dec 20 | 29 | -37 | 17 | 0 |
| 30 Sep 20 | 45 | -26 | 18 | 0 |
| 30 Jun 20 | 57 | -15 | 18 | 0 |
| 31 Mar 20 | 51 | -22 | 18 | 0 |
| 31 Dec 19 | 46 | -28 | 18 | 0 |
| 30 Sep 19 | 34 | -36 | 19 | 13 |
| 30 Jun 19 | 27 | -40 | 18 | 24 |
| 31 Mar 19 | 33 | -28 | 19 | 34 |
| 31 Dec 18 | 29 | -27 | 18 | 41 |
| 30 Sep 18 | 42 | -8 | 21 | 33 |
| 30 Jun 18 | 38 | -8 | 19 | 28 |
| 31 Mar 18 | 28 | -18 | 18 | 24 |
| 31 Dec 17 | 25 | -18 | 18 | 22 |
| 30 Sep 17 | 10 | -32 | 14 | 23 |
| 30 Jun 17 | 7 | -31 | 13 | 22 |
| 31 Mar 17 | 6 | -27 | 11 | 21 |
| 31 Dec 16 | 6 | -23 | 9 | 19 |
| 30 Sep 16 | 5 | -19 | 9 | 15 |
| 30 Jun 16 | 5 | -17 | 9 | 13 |
| 31 Mar 16 | 4 | -15 | 8 | 10 |
| 31 Dec 15 | 3 | -14 | 9 | 8 |
| 30 Sep 15 | 4 | -15 | 10 | 7 |
| 30 Jun 15 | 4 | -13 | 8 | 6 |
| 31 Mar 15 | 4 | -13 | 9 | 6 |
| 31 Dec 14 | 5 | -10 | 7 | 5 |
| 30 Sep 14 | 6 | -5 | 5 | 5 |
| 31 Dec 13 | 12 | 0 | 3 | 9 |
Kwaliteitswinsten: PIRS is currently unprofitable.
Groeiende winstmarge: PIRS is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: PIRS is unprofitable, but has reduced losses over the past 5 years at a rate of 3.4% per year.
Versnelling van de groei: Unable to compare PIRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: PIRS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: PIRS has a negative Return on Equity (-127.33%), as it is currently unprofitable.